Blinatumomab (CD3/CD19 Bite (R) Antibody) results in a high response rate in patients with relapsed non-hodgkin lymphoma (NHL) including mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL)

Authors :: Göbeler, M. E.
Viardot, A.
Noppeney, Richard
Krause, S.
Kallert, S.
Ferstl, B.
Mackensen, A.
Rupertus, K.
Sokler, M.
Kanz, L.
Knop, S.
Topp, M.
Scheele, J.
Nagorsen, D.
Zugmaier, G.
Kufer, P.
Einsele, H.
Bargou, R.
Publication Year :: 2011

Tools